- Autor
-
Pracoviště
2nd Department of Internal Medicine L... 1 Central Hospital of Southern Pest Nat... 1 Department for Viral Hepatitis Univer... 1 Department of Gastroenterology 1st De... 1 Department of Gastroenterology HPB Su... 1 Department of Gastroenterology Hepato... 1 Department of Hepatogastroenterology ... 1 Department of Infectious Diseases Jan... 1 Department of Infectious Diseases and... 1 Institute for Digestive Research and ... 1 Latvian Center of Infectious Diseases... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
- Autor
-
Pracoviště
2nd Department of Internal Medicine L... 1 Central Hospital of Southern Pest Nat... 1 Department for Viral Hepatitis Univer... 1 Department of Gastroenterology 1st De... 1 Department of Gastroenterology HPB Su... 1 Department of Gastroenterology Hepato... 1 Department of Hepatogastroenterology ... 1 Department of Infectious Diseases Jan... 1 Department of Infectious Diseases and... 1 Institute for Digestive Research and ... 1 Latvian Center of Infectious Diseases... 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
PubMed
34155796
DOI
10.1111/liv.14834
Knihovny.cz E-zdroje
According to the recent data presented by Central-European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid-19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.
- MeSH
- antivirové látky terapeutické užití MeSH
- COVID-19 * MeSH
- hepatitida C * diagnóza farmakoterapie epidemiologie MeSH
- lidé MeSH
- prevalence MeSH
- SARS-CoV-2 MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.